Literature DB >> 15065007

Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.

Tomoyuki Tsujikawa1, Riichiro Nezu, Akira Andoh, Takao Saotome, Yoshio Araki, Yoshiyuki Ishizuka, Masaya Sasaki, Shigeki Koyama, Yoshihide Fujiyama.   

Abstract

Acute lower gastrointestinal bleeding is a rare complication of Crohn's disease (CD). Although anti-tumor necrosis factor-alpha (TNF-alpha, infliximab) therapy has been established for patients with inflammatory and fistulous CD, there has been little evidence on whether infliximab is effective for the hemorrhagic type of CD. We report a case of a 31-year-old man with CD who had recurrent sudden-onset bloody stool. After a second surgery, he visited our hospital because of bloody stool. Infusion of infliximab stopped the bleeding and promoted the healing of ulcers in the ileum and ileocolon anastomosis. We suggest that infliximab therapy should be tried to stop acute gastrointestinal bleeding in CD before there is a surgical emergency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15065007     DOI: 10.1007/s00535-003-1290-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  9 in total

1.  Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2.

Authors:  Hua Jiang; Chang-Sheng Deng; Ming Zhang; Jian Xia
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

2.  Infliximab stopped severe gastrointestinal bleeding in Crohn's disease.

Authors:  Satimai Aniwan; Surasak Eakpongpaisit; Boonlert Imraporn; Surachai Amornsawadwatana; Rungsun Rerknimitr
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

3.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

4.  Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy.

Authors:  Manzurul Chowdhury; Norihiko Kudara; Toshimi Chiba; Masaki Endo; Risaburo Akasaka; Kazumitsu Tomita; Saori Fujiwara; Tomomi Mizutani; Tamotsu Sugai; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  Case Rep Gastroenterol       Date:  2009-07-31

Review 5.  Crohn's disease presenting as acute gastrointestinal hemorrhage.

Authors:  Amareshwar Podugu; Kanwarpreet Tandon; Fernando J Castro
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

6.  Infliximab therapy for Crohn's-like disease in common variable immunodeficiency complicated by massive intestinal hemorrhage: a case report.

Authors:  Yuko Akazawa; Fuminao Takeshima; Hiroyuki Yajima; Daisuke Imanishi; Tsutomu Kanda; Kayoko Matsushima; Hitomi Minami; Naoyuki Yamaguchi; Ken Ohnita; Hajime Isomoto; Tomayoshi Hayashi; Masahiro Nakashima; Kazuhiko Nakao
Journal:  BMC Res Notes       Date:  2014-06-22

7.  Prevalence and risk factors of acute lower gastrointestinal bleeding in Crohn disease.

Authors:  Guanwei Li; Jianan Ren; Gefei Wang; Qin Wu; Guosheng Gu; Huajian Ren; Song Liu; Zhiwu Hong; Ranran Li; Yuan Li; Kun Guo; Xiuwen Wu; Jieshou Li
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

8.  Risk factors and prognostic value of acute severe lower gastrointestinal bleeding in Crohn's disease.

Authors:  Jiyoung Yoon; Dae Sung Kim; Ye-Jee Kim; Jin Wook Lee; Seung Wook Hong; Ha Won Hwang; Sung Wook Hwang; Sang Hyoung Park; Dong-Hoon Yang; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742

9.  Diagnostic Value of Computed Tomography in Crohn's Disease Patients Presenting with Acute Severe Lower Gastrointestinal Bleeding.

Authors:  Sunyoung Lee; Byong Duk Ye; Seong Ho Park; Kyung Jin Lee; Ah Young Kim; Jong Seok Lee; Hyun Jin Kim; Suk-Kyun Yang
Journal:  Korean J Radiol       Date:  2018-10-18       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.